menu
    • menu

    Company profile for Virometix

    NEW Drugs in Dev: 2
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases. In an increasingly global world there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases. Fast growing demands, health threats from newly arising complex viral and bacteri...
    Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases. In an increasingly global world there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases. Fast growing demands, health threats from newly arising complex viral and bacterial pathogens and increasingly stringent requirements for stability, safety and tolerability require new approaches to tackling current and future challenges.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    VirometixSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Wagisstrasse 14 CH-8952 Schlieren
    Telephone
    Telephone
    +41 (0) 43 433 86 60
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.virometix.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Virometix Reports Positive Phase 1 Data For V-212 Trail, Vaccine
    Virometix Reports Positive Phase 1 Data For V-212 Trail, Vaccine

    08 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-08/virometix-ag-announces-positive-data-from-phase-1-trial-of-v-212-a-fully-synthetic-serotype-indepe

    PHARMIWEB
    08 Jan 2026
    Share Share
    Virometix Raises $15M for Next-Generation Synthetic V-212 Vaccine
    Virometix Raises $15M for Next-Generation Synthetic V-212 Vaccine

    13 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251112846577/en/Virometix-AG-Announces-Completion-of-%2415-Million-Financing-Round-to-Advance-Development-of-V-212-and-Next-Generation-Synthetic-Vaccines

    BUSINESSWIRE
    13 Nov 2025
    Share Share
    Virometix Completes Enrollment In V-212 Phase I Trial
    Virometix Completes Enrollment In V-212 Phase I Trial

    29 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250929583011/en/Virometix-Announces-Completion-of-Enrollment-in-Phase-I-Trial-of-V-212-a-Fully-Synthetic-Serotype-Independent-Vaccine-Candidate-Against-Streptococcus-Pneumoniae

    BUSINESSWIRE
    29 Sep 2025
    Share Share
    Virometix Appoints Christina as Chair And Board Member
    Virometix Appoints Christina as Chair And Board Member

    08 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241002541613/en

    BUSINESSWIRE
    08 Oct 2024
    Share Share
    Virometix Announces Publication of Key Non-Clinical Proof-of-Concept Data
    Virometix Announces Publication of Key Non-Clinical Proof-of-Concept Data

    14 Jul 2021

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20210714005565/en

    BUSINESS WIRE
    14 Jul 2021
    Share Share
    Virometix Announces Publication of Key Non-Clinical Proof-of-Concept Data
    Virometix Announces Publication of Key Non-Clinical Proof-of-Concept Data

    14 Jul 2021

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20210714005565/en

    BUSINESS WIRE
    14 Jul 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search